Northland Securities Keeps a Buy Rating on Zogenix (ZGNX)


In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Zogenix (ZGNX), with a price target of $60.00. The company’s shares closed last Monday at $42.68.

According to TipRanks.com, Byrnes is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.4% and a 25.3% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Opiant Pharmaceuticals Inc, and Adamas Pharmaceuticals.

Currently, the analyst consensus on Zogenix is a Strong Buy with an average price target of $64.00.

See today’s analyst top recommended stocks >>

Based on Zogenix’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $37.76 million. In comparison, last year the company had a GAAP net loss of $29.04 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts